Friday, February 27, 2015

Reasons for ibrutinib therapy discontinuation in CLL

About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a new study.







from Top Health News — ScienceDaily http://bit.ly/1BKjJJN via Naturally Increase Breast Size At Home

from Tumblr http://bit.ly/1ayj7uE

No comments:

Post a Comment